Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company that regularly publishes updates on its dual business model: development of inflammation and immunology (I&I) biologics and operation of a boutique biologics CDMO under the Scinai Bioservices brand. The news flow around SCNI reflects both scientific progress and the evolution of its contract development and manufacturing activities.
Company press releases highlight several recurring themes. On the R&D side, Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen. News items also cover the PC111 program, a first‑in‑class human anti-Fas Ligand monoclonal antibody being developed for severe dermatological conditions such as pemphigus vulgaris and SJS/TEN through an option agreement to acquire Pincell Srl.
On the CDMO side, Scinai’s news frequently addresses growth in Scinai Bioservices, including revenue contributions from its U.S. subsidiary, new service orders, and infrastructure expansions such as an Israel Innovation Authority grant to fund an advanced sterile fill‑and‑finish system. These updates provide context on how the company is expanding its role as a boutique CDMO serving early-stage biotech clients in Israel, the United States, and Europe.
Investors and industry observers can also find announcements on equity financing arrangements, grant applications and outcomes, participation in sector conferences, and governance or cost-structure changes reported via Form 6‑K. This news page aggregates those releases so readers can follow SCNI’s financial results, pipeline milestones, CDMO capacity developments, and strategic transactions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.